DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA551893
Title:
Adoptive Cellular Therapy Targeting Recurrent Pediatric Brain Cancers During Hematopoietic Recovery from High-Dose Chemotherapy
Descriptive Note:
Annual rept. 1 Apr 2010-31 Mar 2011
Corporate Author:
DUKE UNIV DURHAM NC SCHOOL OF MEDICINE
Report Date:
2011-04-01
Pagination or Media Count:
25.0
Abstract:
A phase III clinical trial evaluating the feasibility, safety, and clinical efficacy of adoptive cellular therapy combined with dendritic cell DC vaccination targeting recurrent medulloblastoma and PNETs was opened for enrollment at Duke University Medical Center during the previous funding period Year 1. DC generation and T cell expansion from archived post-induction chemotherapy specimens from five patients with medulloblastoma was attempted and mature RNA-pulsed DCs were successfully generated from 3 of 5 specimens and successful T cell expansion was achieved from these samples. Limitations in the yield of DCs and T cells from these specimens prompted a modification to the protocol to collect a leukapheresis sample prior to induction chemotherapy. A web-based clinical database for patient and laboratory data storage Oracle Clinical has been created by the Duke Comprehensive Cancer Center Bioinformatics team and is undergoing final beta testing and personnel training for release. Advertising efforts have increased awareness and recent referrals to the study protocol. Two subjects have been enrolled on the protocol, one removed due to final pathology other than medulloblastomaPNET, and the other scheduled for surgical resection next week. Two additional subjects are currently undergoing screening for enrollment.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
